In quick turn, ten23 al­ready look­ing to ex­pand Visp fill-fin­ish site

Last Oc­to­ber, ten23 health ac­quired a Visp, Switzer­land, site from swiss­fil­lon, a lo­cal phar­ma known for its fill-fin­ish op­er­a­tions. On Mon­day, the CD­MO an­nounced that it will ex­pand the Visp man­u­fac­tur­ing site by adding an­oth­er 1,000-square-me­ters of clean room space for de­vice as­sem­bly and pack­ag­ing by the end of this year.

Cost was not dis­closed.

Ten23 picked up swiss­fil­lon just a month af­ter it launched. CEO Hanns-Chris­t­ian Mahler has been a phar­ma guy his whole life and worked at Lon­za as the head of drug prod­uct ser­vices from 2015 un­til his move over to ten23 in March. It’s his sec­ond go at the helm of a start­up, as he co-found­ed drug de­liv­ery com­pa­ny Kriyabio af­ter work­ing at Mer­ck for five years and be­fore that 10 years at Roche. The speed of the swiss­fil­lon pick­up was un­prece­dent­ed, even for Mahler.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER